Fibrostatin sl product pipeline review – 2015 is released

FibroStatin SL - Product Pipeline Review – 2015 Is Released FibroStatin SL - Product Pipeline Review - 2015 Summary Global Markets Direct s, FibroStatin SL Product Pipeline Review - 2015, provides an overview of the FibroStatin SL s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of FibroStatin SLs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of FibroStatin SL including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of FibroStatin SLs human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the FibroStatin SLs pipeline products Reasons to buy - Evaluate FibroStatin SLs strategic position with total access to detailed information on its product pipeline - Assess the growth potential of FibroStatin SL in its therapy areas of focus - Identify new drug targets and therapeutic classes in the FibroStatin SLs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of FibroStatin SL and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of FibroStatin SL - Develop and design in-licensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of FibroStatin SL and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues

1

Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179160/fibrostatin-sl-product-pipeline-review-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179160/fibrostatin-sl-product-pipeline-review-2015 Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 FibroStatin SL Snapshot 4 FibroStatin SL Overview 4 Key Information 4 Key Facts 4 FibroStatin SL - Research and Development Overview 5 Key Therapeutic Areas 5 FibroStatin SL - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 FibroStatin SL - Pipeline Products Glance 9 FibroStatin SL - Early Stage Pipeline Products 9 Preclinical Products/Combination Treatment Modalities 9 Discovery Products/Combination Treatment Modalities 10 FibroStatin SL - Drug Profiles 11 FSMAB-26 11 Product Description 11 Mechanism of Action 11

2

R&D Progress 11 FSSME-12 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 Drug to Inhibit GPBP for Glomerulonephritis and Cancer 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Drugs to Inhibit GPBP for Type 2 Diabetes 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 FibroStatin SL - Locations And Subsidiaries 15 Head Office 15 Appendix 16 Methodology 16 Coverage 16 Secondary Research 16 Primary Research 16 Expert Panel Validation 16 Contact Us 16 Disclaimer 17" width="80" height="40" />Table of Contents Table of Contents 2 3

List of Tables 3 List of Figures 3 FibroStatin SL Snapshot 4 FibroStatin SL Overview 4 Key Information 4 Key Facts 4 FibroStatin SL - Research and Development Overview 5 Key Therapeutic Areas 5 FibroStatin SL - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 FibroStatin SL - Pipeline Products Glance 9 FibroStatin SL - Early Stage Pipeline Products 9 Preclinical Products/Combination Treatment Modalities 9 Discovery Products/Combination Treatment Modalities 10 FibroStatin SL - Drug Profiles 11 FSMAB-26 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 FSSME-12 12 Product Description 12 Mechanism of Action 12 4

R&D Progress 12 Drug to Inhibit GPBP for Glomerulonephritis and Cancer 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Drugs to Inhibit GPBP for Type 2 Diabetes 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 FibroStatin SL - Locations And Subsidiaries 15 Head Office 15 Appendix 16 Methodology 16 Coverage 16 Secondary Research 16 Primary Research 16 Expert Panel Validation 16 Contact Us 16 Disclaimer 17 Read More http://www.idatainsights.com/reports-landing-page.php?id=179160/fibrostatin-sl-productpipeline-review-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and 5

discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.

6